Carlos Sattler

Carlos Sattler currently serves as the Chief Medical Officer at Sorriso Pharmaceuticals since December 2022. With a robust background in clinical development and medical affairs, Carlos held key roles at Pfizer and Amplyx Pharmaceuticals, where responsibilities included overseeing the clinical development program for fosmanogepix and facilitating its transition to Pfizer. Carlos also provided leadership at Halozyme Therapeutics and Sandoz, driving clinical strategies and initiatives for various pharmaceutical products. At Merck & Co., Carlos contributed significantly to the development and launch of the HPV vaccine, serving in multiple capacities from regional director to senior project lead. Carlos holds a Doctor of Medicine (M.D.) from Universidad Peruana Cayetano Heredia and has extensive experience in the medical field, including a role as an attending physician at the Hospital for Sick Children.